BEAUFORT, S.C.--(EON: Enhanced Online News)--According to a new report published by THE SAGE GROUP, 175 million U.S. adults suffer from CVD. Over 3 million have venous ulcers.
“Our cost estimates vastly exceed the commonly quoted range of $1.5-$3.0 billion. Among other reasons, this difference reflects the fact that these older estimates were based on substantially lower ulcer incidence and on 1980s cost data from the UK and Sweden”
“Chronic venous disease afflicts almost twice as many people as all cardiovascular diseases combined, and six times more than those with diabetes. It is one of our most prevalent chronic diseases. However, CVD is significantly underestimated, underdiagnosed and undertreated,” stated Mary L. Yost, President.
“Our venous disease estimates are higher than most of the commonly quoted numbers,” Ms. Yost continued. “Research on U.S. epidemiology is sparse. Our review of the literature concluded that many of the frequently quoted, older studies have significant limitations. This is especially true for venous ulcers with widely varying incidence and prevalence estimates. Prevalence and incidence of venous ulcers is frequently underestimated because approximately half of patients self-treat.”
CVD represents a spectrum of medical conditions involving morphological and functional abnormalities of the venous system. Severity ranges from mild disease characterized by spider veins, reticular veins and telangiectasia to active venous ulcers.
According to Ms. Yost, “The costs of venous disease represent a significant burden on the economy and on patients. Venous ulcers alone cost $21 to $46 billion annually.”
“Our cost estimates vastly exceed the commonly quoted range of $1.5-$3.0 billion. Among other reasons, this difference reflects the fact that these older estimates were based on substantially lower ulcer incidence and on 1980s cost data from the UK and Sweden,” Yost explained.
About the Report: Chronic Venous Disease (CVD) Epidemiology, Costs and Consequences.
The report contains a comprehensive analysis of the peer-reviewed literature published on epidemiology, costs and consequences of chronic venous disease. U.S. prevalence and incidence of CVD, varicose veins, chronic venous insufficiency (CVI) and venous ulcers is estimated. Current economic costs of these diseases are quantified.
Additional information: http://thesagegroup.us/pages/reports/cvd-report.php.
THE SAGE GROUP, a research and consulting company, specializes in peripheral vascular disease in the lower limbs, specifically peripheral artery disease, critical limb ischemia, intermittent claudication, diabetic foot ulcers, venous ulcers and the costs and consequences of amputation. The most recent research focuses on the epidemiology and costs chronic venous disease. Additional information: www.thesagegroup.us.